{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:06:01Z","timestamp":1772600761441,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.oret.2021.12.014","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T17:42:42Z","timestamp":1640626962000},"page":"377-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid"],"prefix":"10.1016","volume":"6","author":[{"given":"Rishi P.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-2590","authenticated-orcid":false,"given":"Chirag","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2299-5251","authenticated-orcid":false,"given":"Giovanni","family":"Staurenghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guruprasad","family":"B","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinfemichael","family":"Gedif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2021.12.014_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","article-title":"Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service","volume":"33","author":"Gale","year":"2019","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2021.12.014_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/vision3030041","article-title":"Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients","volume":"3","author":"Skelly","year":"2019","journal-title":"Vision (Basel)"},{"key":"10.1016\/j.oret.2021.12.014_bib3","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.3390\/ijms21218242","article-title":"Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches","volume":"21","author":"Ricci","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oret.2021.12.014_bib4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.12.014_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/eye.2016.227","article-title":"A\u00a0view of the current and future role of optical coherence tomography in the management of age-related macular degeneration","volume":"31","author":"Schmidt-Erfurth","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2021.12.014_bib6","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.ophtha.2016.05.016","article-title":"Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid","volume":"123","author":"Jaffe","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.12.014_bib7","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.12.014_bib8","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2021.12.014_bib9","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","article-title":"Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD","volume":"35","author":"Chakravarthy","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2021.12.014_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/IAE.0b013e318263cedf","article-title":"Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration","volume":"33","author":"Brown","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.12.014_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41598-018-36704-6","article-title":"Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study","volume":"9","author":"Lai","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2021.12.014_bib12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.12.014_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.oret.2017.10.003","article-title":"Baseline predictors for five-year visual acuity outcomes in the comparison of AMD treatment trials","volume":"2","author":"Ying","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2021.12.014_bib14","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1097\/IAE.0000000000003180","article-title":"Impact of residual subretinal fluid volumes on treatment outcomes in a subretinal fluid-tolerant treat-and-extend regimen","volume":"41","author":"Grechenig","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.12.014_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID Study 24-Month Results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.12.014_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.12.014_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.12.014_bib18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","article-title":"Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration","volume":"122","author":"Schmidt-Erfurth","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.12.014_bib19","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.12.014_bib20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","article-title":"Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.12.014_bib21","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/IAE.0000000000001613","article-title":"Good visual outcome at 1 year in neovascular age-related macular degeneration with pigment epithelium detachment: factors influencing the treatment response","volume":"38","author":"de Massougnes","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.12.014_bib22","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","article-title":"Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents","volume":"138","author":"Evans","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2021.12.014_bib23","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653021003997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653021003997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T07:48:17Z","timestamp":1715154497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653021003997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2468653021003997"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2021.12.014","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2021.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}